Akoya Biosciences, Inc. Sample Contracts
Akoya Biosciences, Inc. 8,700,000 Shares of Common Stock Underwriting AgreementUnderwriting Agreement • June 12th, 2023 • Akoya Biosciences, Inc. • Laboratory analytical instruments • New York
Akoya Biosciences, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 8,700,000 shares of common stock, par value $0.00001 per share, of the Company (the “Underwritten Shares” and, at the option of the Underwriters, up to an additional 1,305,000 shares of common stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of common stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
Standard Contracts
AKOYA BIOSCIENCES, INC. EQUITY DISTRIBUTION AGREEMENTEquity Distribution Agreement • November 7th, 2022 • Akoya Biosciences, Inc. • Laboratory analytical instruments • New York
As further set forth in this agreement (this “Agreement”), Akoya Biosciences, Inc., a Delaware corporation (the “Company”), proposes to issue and sell from time to time through Piper Sandler & Co. (the “Agent”), as sales agent, the Company’s common stock, par value $0.00001 per share (the “Common Stock”) (such shares of Common Stock to be sold pursuant to this Agreement, the “Shares”) on terms set forth herein. Notwithstanding anything to the contrary contained herein, the parties hereto agree that compliance with the limitation set forth in Section 2 of this Agreement on the number of shares of Shares issued and sold under this Agreement shall be the sole responsibility of the Company, and the Agent shall have no obligation in connection with such compliance.
Akoya Biosciences, Inc. STOCK OPTION AGREEMENTStock Option Agreement • April 23rd, 2021 • Akoya Biosciences, Inc. • Laboratory analytical instruments • Delaware
Akoya Biosciences, Inc. (the “Company”) has granted to the Participant named in the Notice of Grant of Stock Option (the “Grant Notice”) to which this Stock Option Agreement (the “Option Agreement”) is attached an option (the “Option”) to purchase certain shares of Stock upon the terms and conditions set forth in the Grant Notice and this Option Agreement. The Option has been granted pursuant to and shall in all respects be subject to the terms and conditions of the Akoya Biosciences, Inc. 2021 Equity Incentive Plan (the “Plan”), as amended to the Date of Grant, the provisions of which are incorporated herein by reference. By signing the Grant Notice, the Participant: (a) acknowledges receipt of, and represents that the Participant has read and is familiar with, the Grant Notice, this Option Agreement, the Plan and a prospectus for the Plan prepared in connection with the registration with the Securities and Exchange Commission of shares issuable pursuant to the Option (the “Plan Prosp
AKOYA BIOSCIENCES, INC. INDEMNIFICATION AGREEMENTIndemnification Agreement • February 5th, 2021 • Akoya Biosciences, Inc. • Laboratory analytical instruments • Delaware
This Indemnification Agreement, dated _______ __, 2021, is made between Akoya BioSciences, Inc., a Delaware corporation (the “Company”), and [______________] (the “Indemnitee”).
AMENDMENT NO. 3 TO CREDIT AND SECURITY AGREEMENT (TERM LOAN)Credit and Security Agreement (Term Loan) • March 7th, 2023 • Akoya Biosciences, Inc. • Laboratory analytical instruments • New York
This CREDIT AND SECURITY AGREEMENT (TERM LOAN) (as the same may be amended, supplemented, restated or otherwise modified from time to time, the “Agreement”) is dated as of October 27, 2020 by and among AKOYA BIOSCIENCES, INC., a Delaware corporation, and each additional borrower that may hereafter be added to this Agreement (each individually as a “Borrower”, and collectively with any entities that become party hereto as Borrower and each of their successors and permitted assigns, the “Borrowers”), MIDCAP FINANCIAL TRUST, a Delaware statutory trust, individually as a Lender, and as Agent, and the financial institutions or other entities from time to time parties hereto, each as a Lender.
Separation Agreement and ReleaseSeparation Agreement • July 5th, 2023 • Akoya Biosciences, Inc. • Laboratory analytical instruments • Massachusetts
THIS SEPARATION AGREEMENT AND RELEASE is entered into between Marilee Moy (the “Executive”) and Akoya Biosciences, Inc. (the “Company”).
AGREEMENT AND PLAN OF MERGER by and among QUANTERIX CORPORATION WELLFLEET MERGER SUB, INC. and AKOYA BIOSCIENCES, INC. Dated as of January 9, 2025Merger Agreement • January 10th, 2025 • Akoya Biosciences, Inc. • Laboratory analytical instruments • Delaware
This AGREEMENT AND PLAN OF MERGER (this “Agreement”) is dated January 9, 2025, by and among Quanterix Corporation, a Delaware corporation (“Parent”), Wellfleet Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (“Merger Sub”), and Akoya Biosciences, Inc., a Delaware corporation (“Company”). Capitalized terms used and not otherwise defined herein have the meanings set forth in ARTICLE 1 below.
VOTING AND SUPPORT AGREEMENTVoting and Support Agreement • January 10th, 2025 • Akoya Biosciences, Inc. • Laboratory analytical instruments • Delaware
THIS VOTING AND SUPPORT AGREEMENT (this “Agreement”) is made and entered into as of January 9, 2025, by and among Akoya Biosciences, Inc., a Delaware corporation (the “Company”) and each of the individuals and entities listed on the signature pages hereto (each, a “Stockholder” and, collectively, the “Stockholders”).
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • March 26th, 2021 • Akoya Biosciences, Inc. • Laboratory analytical instruments • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 27th day of September, 2019, by and among Akoya Biosciences, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”.
AMENDMENT No 1 TO THE LICENSE AGREEMENT EFFECTIVE THE 17TH DAY OF NOVEMBER 2015 BETWEEN STANFORD UNIVERSITY AND AKOYA BIOSCIENCESLicense Agreement • March 26th, 2021 • Akoya Biosciences, Inc. • Laboratory analytical instruments
Effective the 18th day of November, 2016, THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California, and Akoya Biosciences, Inc. (“AKOYA”), a corporation having a principal place of business at 360 Post Street, Suite 601, San Francisco, CA, agree as follows:
AMENDMENT NO. 4 TO CREDIT AND SECURITY AGREEMENT (TERM LOAN)Credit and Security Agreement (Term Loan) • November 14th, 2024 • Akoya Biosciences, Inc. • Laboratory analytical instruments • New York
This AMENDMENT NO. 4 TO CREDIT AND SECURITY AGREEMENT (TERM LOAN) (this “Agreement”) is made as of the 31st day of July, 2024, by and among AKOYA BIOSCIENCES, INC., a Delaware corporation (“Borrower”), MIDCAP FINANCIAL TRUST, a Delaware statutory trust, as Agent (in such capacity, together with its successors and assigns, “Agent”) and the Lenders (as defined in the Credit Agreement referenced below) party hereto.
License and Royalty AgreementLicense and Royalty Agreement • March 26th, 2021 • Akoya Biosciences, Inc. • Laboratory analytical instruments • Delaware
This License and Royalty Agreement (this “Agreement”) is entered into as of September 28, 2018 (the “Effective Date”) by and among PerkinElmer Health Sciences, Inc., a Delaware corporation (“PHS”), Cambridge Research & Instrumentation, Inc., a Delaware corporation (“CRI”) and VisEn Medical Inc., a Delaware corporation (“VisEn” and, together with PHS and CRI, “Licensor”), and Akoya Biosciences, Inc., a Delaware corporation (“Licensee”). PHS, CRI, VisEn and Licensee are each referred to herein individually as a “Party” and collectively, as the “Parties.”
EXCLUSIVE LICENSE AGREEMENT BETWEEN AKOYA BIOSCIENCES, INC. AND UNIVERSITY OF WASHINGTON FOR TECHNOLOGY FOR MOLECULAR PROFILING OF CELLS AND TISSUE SPECIMENS UW COMOTION AGREEMENT 43158AExclusive License Agreement • March 26th, 2021 • Akoya Biosciences, Inc. • Laboratory analytical instruments • Washington
This exclusive patent license agreement (this “Agreement”), effective as of June 26, 2018 (the “Effective Date”), is made and entered into between the University of Washington, a public institution of higher education and an agency of the state of Washington, (“University”), and Akoya Biosciences, Inc., a Delaware (“Company”).
AKOYA BIOSCIENCES, INC. INDEMNIFICATION AGREEMENTIndemnification Agreement • December 13th, 2024 • Akoya Biosciences, Inc. • Laboratory analytical instruments • Delaware
This Indemnification Agreement, dated _______ __, 2024, is made between Akoya Biosciences, Inc., a Delaware corporation (the “Company”), and [______________] (the “Indemnitee”).
TRANSITION SERVICES AGREEMENTTransition Services Agreement • March 26th, 2021 • Akoya Biosciences, Inc. • Laboratory analytical instruments • Delaware
This Transition Services Agreement (together with the Service Schedules attached hereto, this “TSA”) is made as of September 28, 2018 (the “Effective Date”) by and between PerkinElmer Health Sciences, Inc., a Delaware corporation (“Service Provider”), and Akoya Biosciences, Inc., a Delaware corporation (the “Service Recipient”). Service Provider and Service Recipient are each referred to herein individually as a “Party” and collectively, as the “Parties.”
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...Exclusive (Equity) Agreement • March 26th, 2021 • Akoya Biosciences, Inc. • Laboratory analytical instruments • California
This Agreement between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California, and Akoya Biosciences, Inc. (“AKOYA”), a Delaware corporation having a principal place of business at 360 Post Street, Suite 601, San Francisco, California, is effective on the 17th day of November, 2015 (“Effective Date”).
AMENDMENT NO. 5 to CREDIT AND SECURITY AGREEMENT (TERM LOAN)Amendment No. 5 to Credit and Security Agreement (Term Loan) • March 17th, 2025 • Akoya Biosciences, Inc. • Laboratory analytical instruments • New York
This AMENDMENT No. 5 TO CREDIT AND SECURITY AGREEMENT (TERM LOAN) (this “Agreement”) is made as of the 1st day of November, 2024, by and among AKOYA BIOSCIENCES, INC., a Delaware corporation (“Borrower”), MidCap FINANCIAL Trust, a Delaware statutory trust, as Agent (in such capacity, together with its successors and assigns, “Agent”) and the Lenders (as defined in the Credit Agreement referenced below) party hereto.
